The role of extrahepatic metabolism in the pharmacokinetics of the targeted covalent inhibitors afatinib, ibrutinib, and neratinib

Drug Metabolism and Disposition

Volumn 43, Issue 3, 2015, Pages 375-384

  Shibata, Yoshihiro ^a   Chiba, Masato ^a  

^a Tsukuba Wellness Research   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; GLUTATHIONE; GLUTATHIONE TRANSFERASE; IBRUTINIB; NERATINIB; N-(4-(3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO)-3-CYANO-7-ETHOXY-6-QUINOLYL)-4-(DIMETHYLAMINO)-2-BUTENAMIDE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE;

ALLOMETRY; ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CRYOPRESERVATION; CYTOSOLIC FRACTION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DOSE ESCALATION; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL; LIVER CLEARANCE; MALE; NONHUMAN; RAT; ANIMAL; CYTOSOL; DOG; KIDNEY; LIVER; MACACA FASCICULARIS; METABOLISM;

ANIMALIA; CANIS FAMILIARIS; RATTUS;

ANIMALS; AREA UNDER CURVE; CYTOSOL; DOGS; GLUTATHIONE; HEPATOCYTES; HUMANS; KIDNEY; LIVER; MACACA FASCICULARIS; MALE; PYRAZOLES; PYRIMIDINES; QUINAZOLINES; QUINOLINES; RATS;

EID: 84921760448     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.061424     Document Type: Article

References (46)

1. Abbas R, Hug BA, Leister C, Burns J, and Sonnichsen D (2011) Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. Br J Clin Pharmacol 71:522-527.
2. Abbas R, Hug BA, Leister C, and Sonnichsen D (2012) A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor. Cancer Chemother Pharmacol 70:191-199.
3. Akabane T, Tabata K, Kadono K, Sakuda S, Terashita S, and Teramura T (2010) A comparison of pharmacokinetics between humans and monkeys. Drug Metab Dispos 38:308-316.
4. Andersen ME, Clewell HJ, 3rd, Gargas ML, Smith FA, and Reitz RH (1987) Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol Appl Pharmacol 87:185-205.
5. Armstrong RN (1997) Structure, catalytic mechanism, and evolution of the glutathione transferases. Chem Res Toxicol 10:2-18.
6. Awasthi YC, Sharma R, and Singhal SS (1994) Human glutathione S-transferases. Int J Biochem 26:295-308.
7. Baillie TA (2006) Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology. Chem Res Toxicol 19:889-893.
8. Böhme A, Thaens D, Paschke A, and Schüürmann G (2009) Kinetic glutathione chemoassay to quantify thiol reactivity of organic electrophiles-application to alpha, beta-unsaturated ketones, acrylates, and propiolates. Chem Res Toxicol 22:742-750.
9. Cameron F and Sanford M (2014) Ibrutinib: first global approval. Drugs 74:263-271.
10. Carmi C, Mor M, Petronini PG, and Alfieri RR (2012) Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. Biochem Pharmacol 84:1388-1399.
11. Center for Drug Evaluation and Research (CDER) (2012) Gilotrif. FDA application no. (NDA) 201292/S-001. NDA review, approval package. Boehringer Ingelheim Pharmaceuticals, Inc., July 23, 2013. U.S. Food and Drug Administration, Rockville, MD.
12. Center for Drug Evaluation and Research (CDER) (2013) Imbruvica. FDA application no. (NDA) 205552Orig1s000. NDA review, approval package. Pharmacyclics, Inc., November 13, 2013. U.S. Food and Drug Administration, Rockville, MD.
13. D'Souza RW and Andersen ME (1988) Physiologically based pharmacokinetic model for vinylidene chloride. Toxicol Appl Pharmacol 95:230-240.
14. D'Souza RW, Francis WR, and Andersen ME (1988) Physiological model for tissue glutathione depletion and increased resynthesis after ethylene dichloride exposure. J Pharmacol Exp Ther 245:563-568.
15. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
16. de Waziers I, Cugnenc PH, Yang CS, Leroux JP, and Beaune PH (1990) Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 253:387-394.
17. Fabrini R, Bocedi A, Dawood KF, Turella P, Stella L, Parker MW, Pedersen JZ, Federici G, AntoniniG, andRicciG (2011) The extended catalysis of glutathione transferase. FEBS Lett 585: 341-345.
18. Gandhi L, Bahleda R, Tolaney SM, Kwak EL, Cleary JM, Pandya SS, Hollebecque A, Abbas R, Ananthakrishnan R, and Berkenblit A, et al. (2014) Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol 32:68-75.
19. Garuti L, Roberti M, and Bottegoni G (2011) Irreversible protein kinase inhibitors. Curr Med Chem 18:2981-2994.
20. Ito Y, Suenaga M, Hatake K, Takahashi S, Yokoyama M, Onozawa Y, Yamazaki K, Hironaka S, Hashigami K, and Hasegawa H, et al. (2012) Safety, efficacy and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors: a Phase 1 dose-escalation study. Jpn J Clin Oncol 42:278-286.
21. Iwatsubo T, Suzuki H, and Sugiyama Y (1997) Prediction of species differences (rats, dogs, humans) in the in vivo metabolic clearance of YM796 by the liver from in vitro data. J Pharmacol Exp Ther 283:462-469.
22. Kalgutkar AS and Dalvie DK (2012) Drug discovery for a new generation of covalent drugs. Expert Opin Drug Discov 7:561-581.
23. Keating GM (2014) Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer. Drugs 74:207-221.
24. Liebler DC (2008) Protein damage by reactive electrophiles: targets and consequences. Chem Res Toxicol 21:117-128.
25. Lin JH, Sugiyama Y, Awazu S, and Hanano M (1982) Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data. J Pharmacokinet Biopharm 10:649-661.
26. Molife LR, Rudman SM, Alam S, Tan DS, Kristeleit H, Middleton G, Propper D, Bent L, Stopfer P, and Uttenreuther-Fischer M, et al. (2013) Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors. Cancer Chemother Pharmacol 72:1213-1222.
27. Murakami H, Tamura T, Takahashi T, Nokihara H, Naito T, Nakamura Y, Nishio K, Seki Y, Sarashina A, and Shahidi M, et al. (2012) Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). Cancer Chemother Pharmacol 69:891-899.
28. Naritomi Y, Terashita S, Kagayama A, and Sugiyama Y (2003) Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab Dispos 31:580-588.
29. Niro R, Byers JP, Fournier RL, and Bachmann K (2003) Application of a convective-dispersion model to predict in vivo hepatic clearance from in vitro measurements utilizing cryopreserved human hepatocytes. Curr Drug Metab 4:357-369.
30. Nishimuta H, Sato K, Mizuki Y, Yabuki M, and Komuro S (2010) Prediction of the intestinal first-pass metabolism of CYP3A substrates in humans using cynomolgus monkeys. Drug Metab Dispos 38:1967-1975.
31. Nishimuta H, Sato K, Mizuki Y, Yabuki M, and Komuro S (2011) Species differences in intestinal metabolic activities of cytochrome P450 isoforms between cynomolgus monkeys and humans. Drug Metab Pharmacokinet 26:300-306.
32. Pacifici GM, Franchi M, Bencini C, Repetti F, Di Lascio N, and Muraro GB (1988) Tissue distribution of drug-metabolizing enzymes in humans. Xenobiotica 18:849-856.
33. Reitz RH, Mendrala AL, and Guengerich FP (1989) In vitro metabolism of methylene chloride in human and animal tissues: use in physiologically based pharmacokinetic models. Toxicol Appl Pharmacol 97:230-246.
34. Roberts MS and Rowland M (1986) Correlation between in-vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model. J Pharm Pharmacol 38:177-181.
35. Rowe JD, Nieves E, and Listowsky I (1997) Subunit diversity and tissue distribution of human glutathione S-transferases: interpretations based on electrospray ionization-MS and peptide sequence-specific antisera. Biochem J 325:481-486.
36. Schwöbel JA, Wondrousch D, Koleva YK, Madden JC, Cronin MT, and Schüürmann G (2010) Prediction of Michael-type acceptor reactivity toward glutathione. Chem Res Toxicol 23: 1576-1585.
37. Shibata Y, Kuze J, and Chiba M (2014) Utility of cryopreserved hepatocytes suspended in serum to predict hepatic clearance in dogs and monkeys. Drug Metab Pharmacokinet 29: 168-176.
38. Shibata Y, Takahashi H, Chiba M, and Ishii Y (2002) Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method. Drug Metab Dispos 30:892-896.
39. Shibata Y, Takahashi H, and Ishii Y (2000) A convenient in vitro screening method for predicting in vivo drug metabolic clearance using isolated hepatocytes suspended in serum. Drug Metab Dispos 28:1518-1523.
40. Singh J, Petter RC, Baillie TA, and Whitty A (2011) The resurgence of covalent drugs. Nat Rev Drug Discov 10:307-317.
41. Stopfer P, Marzin K, Narjes H, Gansser D, Shahidi M, Uttereuther-Fischer M, and Ebner T (2012) Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol 69:1051-1061.
42. Takahashi M, Washio T, Suzuki N, Igeta K, Fujii Y, Hayashi M, Shirasaka Y, and Yamashita S (2008) Characterization of gastrointestinal drug absorption in cynomolgus monkeys. Mol Pharm 5:340-348.
43. Watanabe T, Sagisaka H, Arakawa S, Shibaya Y, Watanabe M, Igarashi I, Tanaka K, Totsuka S, Takasaki W, and Manabe S (2003) A novel model of continuous depletion of glutathione in mice treated with L-buthionine(S, R)-sulfoximine. J Toxicol Sci 28:455-469.
44. Wind S, Schmid M, Erhardt J, Goeldner RG, and Stopfer P (2013) Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours. Clin Pharmacokinet 52:1101-1109.
45. Wong KK, Fracasso PM, Bukowski RM, Lynch TJ, Munster PN, Shapiro GI, Jänne PA, Eder JP, Naughton MJ, and Ellis MJ, et al. (2009) A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 15:2552-2558.
46. Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, Ang J, Temple G, Bell S, and Shahidi M, et al. (2010) Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 28:3965-3972.